PALVELLA THERAPEUTICS, INC. 8-K

What Happened

• Palvella Therapeutics, Inc. (Nasdaq: PVLA) filed an 8-K (Item 8.01) reporting that the Nasdaq Listing Qualifications Department approved moving its common stock listing from the Nasdaq Capital Market to the Nasdaq Global Market. Approval was received on May 11, 2026, and the transfer became effective at the open of business on May 13, 2026. The company’s ticker symbol remains "PVLA." The filing was signed by Chief Financial Officer Matthew Korenberg on May 13, 2026.

Key Details

• Approval date: May 11, 2026 (Nasdaq Listing Qualifications Department).
• Effective date: May 13, 2026 (open of business).
• Listing change: Nasdaq Capital Market → Nasdaq Global Market.
• Ticker unchanged: "PVLA"; filing signed by CFO Matthew Korenberg.

Why It Matters

• The 8-K documents an administrative change in the exchange tier for Palvella’s common stock; it does not report any change to the company’s outstanding shares, ticker symbol, corporate governance, or financial results. Investors should note the effective date and continue to watch the company’s future filings for any material operational or financial developments.